News

Janssen Pharmaceutica, Xian-Janssen Pharmaceutical and the Qinshihuang Terracotta Army Museum of Xian sign a NEW agreement to establish a world-class research laboratory for conservation and restoration of relics

New contract for a value of approx. US $ 2 million (1 mio in cash)

Terracotta Army Museum now officially declared mold-free

17th October 2006, Xian - Janssen Pharmaceutica, Xian-Janssen Pharmaceutical, and the Qinshihuang Terracotta Army Museum of Xian in China today signed a new cooperation agreement for the creation of a world-class research lab for the conservation and restoration of relics and heritage. The agreement will also include the sharing of Janssen's innovative technology for conservation and restoration with Chinese scientists.

In addition, the agreement will lead to the upgrading of the museum's current scientific research laboratory - the Dr. Paul Janssen Laboratory for Advanced Material Protection Research. The laboratory first officially opened on June 5, 2001 - will develop expertise in ancient polychrome pottery research and become a scientific-technical research center on the conservation of relics and as a training centre for cultural relics conservation. The lab will be equipped with advanced instruments, offer reliable data and put conservation into practice effectively. The laboratory will also carry out research on the environmental physico-chemical factors that influence the conservation of cultural relics.

The signing ceremony took place in Xian in the presence of

• Mr. Yuan Chunqing, the Governor of the Shaanxi Province
• Mr. Paul Stoffels, Company Group Chairman Worldwide Research & Development, Johnson & Johnson
• Mr. Wu Yongqi, Director of the Terracotta Army Museum of Xian
• Mr. Pen Hok Cheah, President of Xian-Janssen

Dirk Collier (rechts) ondertekende voor Janssen Pharmaceutica.

The agreement stipulates a five-year cooperation period between 2007 and 2011, and allows specifically for the creation of

• A multifunctional lab for relics restoration
• An analytical laboratory for materials pertaining to cultural relics, and
• A laboratory for the study of the preservation of relics.

This project will be fully funded by Janssen in the form of cash, instruments and equipment, and the training of the Museum technical staff. In addition, further scientific research on the restoration of relics will be undertaken.

Under the terms of the agreement, Janssen will also establish

• A Dr. Paul Janssen Culture Relic Research & Protection Center
• Create the first-ever Emperor Qin Shihuang Terracotta Army Museum - Dr. Paul Janssen Culture Relic Fund and
• The Emperor Qin Shihuang Terracotta Army Museum - Dr. Paul Janssen Conservation Award.

Janssen Pharmaceutica is one of the most innovative pharmaceutical companies and is a leader in the field of dermatology. It is also recognized as a worldwide expert in antifungal treatments. Janssen antifungal products have helped treat millions of patients in China over the past 20 years, as well as treating and protecting China's ancient cultural relics. Today, the Terracotta Army Museum is one of the third largest cultural relics protection centers in China.

The new cooperation agreement follows a previous three-year contract, signed in September 2000 between Janssen and the Museum, aimed at finding out which molds had caused the damage to the Terracotta Warriors and how further decay could be prevented. That first agreement led to the implementation of effective programs to eradicate the fungal problem as well as the establishment of the Dr. Paul Janssen Laboratory for Advanced Material Protection Research. The laboratory is considered as one of the most advanced mycology laboratories in China. It not only laid the foundation for mildew prevention research in the field of terracotta but also created new methods of mildew prevention for ancient relics of silk, wood, bronze ware and ancient mummified corpses.

Janssen Pharmaceutica is a worldwide Center of Excellence of integrated R&D, production, and general services, within the Johnson & Johnson group. With more than 80 drugs to its credit, the company is one of the most innovative worldwide, and its products are used the world over in both human and animal health, and in material protection.

Xian-Janssen Pharmaceutical Ltd. (XJP) is a joint venture between Janssen Pharmaceutica of Belgium and four Chinese companies : Shaanxi Han Jiang Pharmaceutical Ltd., Shaanxi Pharmaceutical Industry Corporation, China National Pharmaceutical Industry Corporation, China National Pharmaceutical Foreign Trade Corporation . XJP is one of the largest pharmaceutical joint ventures in China and the leading pharmaceutical company in the country, with more than 2000 employees.

For further information, please contact

Stefan Gijssels, Vice President Public Affairs